Mounting Regulatory and Legal Challenges Pressure Hims & Hers Stock
17.02.2026 - 13:21:05 | boerse-global.de
The telehealth company Hims & Hers finds itself navigating a perfect storm of regulatory scrutiny and legal action, leading to significant pressure on its share price. The stock has lost more than half its value since the start of the year as several critical issues converge.
A primary source of tension stems from the company’s brief foray into offering unapproved, compounded weight-loss medications. According to a Reuters report, the U.S. Food and Drug Administration (FDA) has referred Hims & Hers to the Department of Justice (DoJ). This action followed the FDA’s stated intention to take decisive steps to restrict GLP-1 ingredients in compounded drugs that lack its Read more...
US4330001060 | MOUNTING
